期刊名称：CHEMICAL BIOLOGY & DRUG DESIGN
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and Scope
Chemical Biology & Drug Design is a peer-reviewed scientific journal that is dedicated to the advancement of innovative science, technology and medicine with a focus on the multidisciplinary fields of chemical biology and drug design. It is the aim of Chemical Biology & Drug Design to capture significant research and drug discovery that highlights new concepts, insight and new findings within the scope of chemical biology and drug design.
The following scientific topics will exemplify the scope of the journal:
Protein, peptide, peptidomimetic, nucleic acid, lipids, carbohydrate and natural product chemical biology and drug design
Receptor agonist/antagonist, protease substrate/inhibitor, and signal transduction modulator chemical biology and drug design
Small-molecule diversity and synthetic methods important to investigate chemical space relationships to drug discovery
-based drug design, molecular modeling, virtual screening and related in silico chemoinformatics technologies
NMR, X-ray crystallography, calorimetry and related biophysical technologies
Therapeutic target proteomics, chemical genomics and molecular screening technologies
Emerging chemical, biological and drug design concepts of significance to pharmacology, ADMET and drug delivery.
Novel proof-of-concept ligands and breakthrough medicines (CB&DD thematic issues)
Types of articles published in CB&DD:
Editorial
Commentary
In Memoriam
R&D Spotlight
R&D Tutorial
Perspective
Review Research Article
Research Lette
Science Philosophy
Medicine Pipeline
Technology Platform
Words of Wisdom
World Project Initiative
Who's Who in Chemical Biology & Drug Design
Calendar of Events
Special features will include:
Thematic issue on Molecular Armamentarium of Chemical and Biological Medicines
Thematic issue on Innovative Technologies for Basic Research and Drug Discovery
标题历史记录详细信息
| Formerly (until 2006): Journal of Peptide Research (Print) (丹麦) (1397-002X) |
| Which was formed by the merger of (1988-1997): Peptide Research (美国) (1040-5704) |
| (1972-1997): International Journal of Peptide and Protein Research (丹麦) (0367-8377) |
| Which was formerly (1969-1972): International Journal of Protein Research (丹麦) (0020-7551) |
Instructions to Authors
Author Guidelines
Electronic Submission of Manuscripts
To submit a manuscript for Chemical Biology & Drug Design please visit http://mc.manuscriptcentral.com/cbdd. Please note that this journal does not accept Microsoft Word 2007 documents at this time. If you are using the beta version of Microsoft Word 2007 please use Word's "Save As" option to save your document as an older (.doc) file type.
If electronic submissions are impossible, please contact the Editorial Office at:
Tomi K. Sawyer, Editor-in-Chief
Chemical Biology & Drug Design
Pfizer Research Technology Center
620 Memorial Drive
Cambridge, MA 02139
USA
Tel: (617)551 3307
E-mail: editor@cbdd.org
Exclusive Licence Form - Authors will be required to sign an Exclusive Licence Form (ELF) for all papers accepted for publication. Signature of the ELF is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. Please note that signature of the Exclusive Licence Form does not affect ownership of copyright in the material. (Government employees need to complete the Author Warranty sections, although copyright in such cases does not need to be assigned). After submission authors will retain the right to publish their paper in various medium/circumstances (please see the form for further details). To assist authors an appropriate form will be supplied by the editorial office. Alternatively, authors may like to download a copy of the form here.
Description of Manuscripts Types
Chemical Biology & Drug Design welcomes correspondence in the following categories:
Reviews will be focused on a significantly important theme to chemical biology and drug design. Reviews should incorporate a judicious use of tables, figures, schemes and references.
Perspectives will follow the general scope of reviews but will have a focus on the future predictions rather than past results.
Research Articles will provide detailed description of scientific findings within the scope of the journal and formatted according to guidance highlighted below with respect to subheadings, inclusion of tables and/or figures, reference style, etc.
Research Letters will be short version of a Research Article, but should be continuous text (subheadings for 'Results and Discussion' and 'Conclusions and Future Directions' are optional).
STRONG> Editorials will be invited by the Editor to provide focused viewpoints of specific topics of interest, and written as continuous text with no subheadings.
Commentaries will be invited by the Editor to provide focused viewpoints of specific topics of interest, and written as continuous text with no subheadings.
In Memoriam will be invited by the Editor to provide focused description of the recent passing away of a prominent scientist, and written as continuous text with no subheadings.
R&D Spotlight will be invited by the Editor to provide focused analysis of key academic, government and industrial groups, highlighting their contributions to research and development.
R&D Tutorial will be invited by the Editor to provide focused teaching of specific concepts, methods, technologies or other information of significance to research and development.
Medicine Pipeline will be invited by the Editor to provide focused description of breakthrough drugs or in-the-clinic molecules, and written as continuous text with no subheadings.
Science Philosophy will be invited by the Editor to provide focused description of milestone basic research and drug discovery, and written as continuous text with no subheadings.
Technology Platform will be invited by the Editor to provide focused description of state-of-the-art R&D tools, methods and knowledge systems significant to chemical biology and drug design, and written as continuous text with no subheadings.
Words of Wisdom will be invited by the Editor to provide focused viewpoints related to the interface of medicine, science or technology with ethics, religion or spirituality in search of truth, and written as continuous text with no subheadings.
Who's Who in Chemical Biology & Drug Design will be invited by the Editor to provide focused biographic abstract compilations of key academic, government and industrial scientists engaged in work relevant to the scope of the journal.
Calendar of Events will be at the discretion of the Editor to list relevant scientific meetings relevant to the scope of the journal.
Guidelines for Research Article Manuscript Preparation
nbsp;Title must be concise and contain no more than 50 words. The title page should include a short running title of no more than 50 characters, 5-10 key words, complete names of institutions for each author, and the name, address, phone number, fax number and e-mail address for the corresponding author.
nbsp;Abbreviations CB&DD adheres to the conventions outlined in Units, Symbols and Abbreviations: A guide for medical and scientific editors and authors. Non-standard abbreviations must be used 3 or more times and written in full when first used.
nbsp;Abstract is limited to 200 words. References must be cited in full.
nbsp;Introduction should be focused; exhaustive literature overviews are not appropriate.
nbsp;Methods and Materials must contain sufficient detail such that, in combination with the references cited, all experiments reported can be fully reproduced.
nbsp;Results and Discussion can be combined if necessary or can be written as separate sections.
nbsp;Conclusions and Future Directions can be combined if necessary or can be written as separate sections.
EM> Acknowledgments All sources of institutional, private and corporate financial support for the work within the manuscript must be fully acknowledged, and any potential conflicts of interest noted.
nbsp;References should be cited in the text parenthetically by number, listed at the end of the manuscript in the order cited and include only articles that have been published or are currently in press. 'In press' manuscripts that are necessary to understand and evaluate the submitted manuscript must be included at the time of submission. CB&DD uses the Vancouver style of references that is outlined below. In all cases, the author list should be abbreviated to et al. after 15 authors, and the journal name, volume and page numbers replaced by the statement 'In Press' where appropriate.
Journal Article
1. Sawyer, T.K. (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 13: 1-19.
Article in Book
2. Sawyer, T.K. (1997) Peptidomimetic and nonpeptide drug discovery: Impact structure-based drug design. In: Veerapandian, P., editor. Structure-Based Drug Design: Diseases, Targets, Techniques and Developments. Marcel Dekker, New York, USA, p. 559-634.
Complete Book
3. Borchardt, R.T., Freidinger, R.M., Sawyer, T.K., Smith, P.L. (1998) Integration of Pharmaceutical Discovery and Development: Case Histories. Plenum Publishing Corp., New York, USA.
We recommend the use of a tool such as EndNote or Reference Manager for reference management and formatting.
EndNote reference styles can be searched for here:http://www.endnote.com/support/enstyles.asp
Reference Manager reference styles can be searched for here:http://www.refman.com/support/rmstyles.asp
EM> Notes should be listed in the text as superscript lower case letters, a, b, c, etc and listed at the end of the manuscript (following the References section) in the order cited in the text. Generally 'Notes' are used to define some technical points or comments related to the experimental descriptions (e.g., Methods and Materials section). Websites should also be listed in the Notes section and not within the reference list. Other usage of the Notes section may be permitted as dependent on editorial review.
EM> Figures and schemes All figures should be planned to fit within either 1 column width (8 cm), 1.5 column widths (13 cm) or 2 column widths (17 cm), and must be suitable for photocopy reproduction from the printed version of the manuscript. The editors recommend using the guidelines below.nbsp;All figures should be submitted at final reproduction size.
nbsp;Blackwell Publishing's generic guidelines on the submissions of electronic artwork are available here, however, please note that the Publisher recommends that authors do not use the PDF file format for manuscripts or graphics files when submitting manuscripts for Chemical Biology & Drug Design
nbsp;Figure Legends and Tables should be a separate section of the manuscript. Tables should be double spaced with no vertical rulings, with a single bold ruling beneath the column titles. Units of measurement must be included in the column title.
nbsp;Supplemental Material It should be clearly stated at the time of submission that the Supplementary Material is intended to be made available through the online edition. The availability of Supplementary Material should be indicated in the main manuscript by a paragraph, to appear after the References, headed 'Supplementary Material' and providing titles of figures, tables, etc. The Supplementary Material should be submitted in its final form. No changes can be made subsequently by the Editorial Office or the Publisher. This Supplementary Material is an integral part of the article and will be reviewed accordingly. When submitting Supplementary Material via the electronic submission website authors should choose 'Supplementary File' from the file designation drop down list on the File Upload page. Further details on Supplementary Material are available here. Please note that the Publisher recommends that authors do not use the PDF file format for manuscripts or graphics files.
Guidelines for Research Letter Manuscript Preparation
nbsp;Title (see guidelines for Research Article)
nbsp;Abbreviations (see guidelines for Research Article)
nbsp;Abstract, Introduction, Methods and Materials, Results and Discussion, Conclusions and Future Directions. Headings are not required.
nbsp;Acknowledgments, References (see guidelines for Research Article).
nbsp;Figures, Figure Legends and Tables (see guidelines for Research Article).
nbsp;Supplemental Material (see guidelines for Research Article).
Guidelines for 'Review' and 'Perspective' Manuscript Preparation
nbsp;Title (see guidelines for Research Article)
nbsp;Abbreviations (see guidelines for Research Article)
nbsp;Abstract, Introduction, Methods and Materials, Results and Discussion, Conclusions and Future Directions. Headings are not required.
nbsp;Acknowledgments, References (see guidelines for Research Article).
nbsp;Figures, Figure Legends and Tables (see guidelines for Research Article).
Guidelines for Describing Chemical, Biological, Drug Design and Related Experimental Information
Chemical (and Related) Experimental Information. Chemical reactions should be shown for synthetic transformations of significance to the theme of the manuscript. The chemical name and compound number should be described within the Methods and Materials for each compound synthesized in those manuscripts focused, in part, on chemistry. Purity and proof-of-structure criteria of synthetic compounds should be described as well as methods (e.g., HPLC, TLC, elemental analysis, NMR, X-ray crystallography) used to determine such chemical properties. For manuscripts having significant amounts of such data, it is recommended that the Supplementary Information option be considered to an appropriate extent. For combinatorial libraries, general characterization of the libraries and more detailed analysis of specific molecules from the libraries should be considered with respect to purity and proof-of-structure criteria. Chemical structures should be prepared using a chemical drawing program (e.g., ChemDraw) as standard practice and saved as TIFF or EPS files in submitting along with Tables and manuscript (text and references). It is highly recommended that chemical structure drawings be prepared using American Chemical Society guidelines, including: chain angles at 120 degrees, bond spacing 18% of width, fixed length 14.4 pt (0.508 cm or 0.2 inch), bold width 2.0 pt (0.071 cm or 0.0278 inch), line width 0.6pt (0.021 cm or 0.0084 inch), margin width 1.6 pt (0.056cm or 0.0222 inch), hash spacing 2.5 pt (0.088 cm or 0.0347 inch). Furthermore, chemical structure text is suggested to follow Arial or Helvetica font and 10 or 12 pt size.
Biological (and Related) Experimental Information. Biological testing must be described in sufficient detail for all key molecules highlighted in the manuscript (i.e., lead compounds). Biological testing methods and materials must be described in sufficient details to enable others to repeat such work. Statistical analysis for biological data should be provided in most circumstances. If such results are impeded for some particular reason, then judicious description of key factors in the biological studies (e.g., number of determinations, an indication of variability and reliability) should be given. Doses and concentrations of drug samples should be expressed in typical units such as mg/kg or mol/kg. Drug delivery, pharmacokinetics, toxicology, and in vivo efficacy should each be detailed, including detailed description of the dose of drug and its formulation as well as route of administration.
Drug Design (and Related) Experimental Information. Drug design and related computational, chemoinformatics, and structural biology experimental methods must be detailed with appropriate references to both hardware and software used. For macromolecular structures (apoprotein and/or complexes thereof), authors must deposit the atomic coordinates with the Protein Data Bank at Rutgers University (http://rscb.rutgers.edu/pdb/inex.html), and the file name provided in the manuscript (i.e., within the Methods and Materials or as a reference/footnote). Programs (software) used for drug design should be described with inclusion of the commercial source if appropriate. Detailed description of complex molecular modelling studies (i.e., conformational calculations) should be provided.
Additional Information for Manuscript Preparation, Submission, and Publication (Proofs, Offprints, OnlineEarly)
Articles should not ordinarily exceed 12 printed pages. Additional pages must be paid by the author at the rate of DKK 800, GBP 70 (+ VAT) or US $100 per page. Figures and references should conform to the conventions of CB&DD as described above.
Care in grammatical construction is essential, and in view of page limitations for the Journal, brevity consistent with clarity is very important. At the time of submission, contributors must conform to these Instructions, and to acceptable standards of English style and usage. Please correct all errors in typing, and check the spelling of proper names, such as authors referenced, and words in foreign languages. Verify the accuracy of direct quotations, bibliographic references, and all analytical data, as well as the numerical numbers given for both Tables and Figures mentioned in the text. Indicate in the margins when Tables and Figures are first mentioned in the text.
For nomenclature, abbreviations, symbols, and conventions, authors should refer to the latest standards as used in the Journal of Medicinal Chemistry, the Journal of Biological Chemistry, and related journals which focus on aspects of chemistry, biology, drug design. Some common abbreviations include mp, bp, oC, K, min, h, mL, µL, g, mg, µg, cm, mm, nm, mM, µM, nM, pM, ppm, TLC, HPLC, RP-HPLC, GC, NMR, UV, and IR. Other abbreviations not in general use in the text should be collected as a single footnote which should be placed on p. 3 of the paper as a separate item.
Illustrations - All illustrations are regarded as figures (not schemes) and should be numbered consecutively in their order of appearance with Arabic numerals. They should be submitted on a separate sheet generally of the same size as the text. Each illustration should be numbered on the back with an indication of its proper alignment on the printed page, and the names of the authors. They should be written or produced so that the general meaning of each illustration can be understood without reference to the text. Figures should be planned to fit the proportions of the printed page. Any lines, numbers or lettering that are to appear in the illustrations should be large enough for the necessary reduction. Line drawings and graphs which are not submitted as photographic reproductions should be drawn with black India ink on white paper, and should be about twice the size of the finished blocks. Computer generated structures, graphs, and figures are also accepted provided they are printed with high-contrast laser printers using high quality white paper.
Please supply electronic versions of your figures. These should be supplied as EPS or TIFF. Each complete figure should be placed in a separate file. Avoid using tints if possible; if shading is essential to the understanding of the figure, try to make it coarse. Information on our digital illustration standards can be obtained at: http://www.blackwellpublishing.com/authors/illustration.asp.
Pre-submission English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found here. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
Colour illustrations
Original colour transparencies as well as two sets of colour prints should be submitted. On the back of each illustration should be the name of the Journal, the name(s) of the author(s), and the Figure number and its orientation (top), as well as the title of the paper.
It is the policy of Chemical Biology and Drug Design for authors to pay the full cost for the reproduction of their colour artwork, unless otherwise stated by the Editor at time of acceptance.
Therefore, please note that if there is colour artwork in your manuscript when it is accepted for publication, Blackwell Publishing require you to complete and return a colour work agreement form (http://www.blackwellpublishing.com/pdf/SN_Sub2000_X_CoW.pdf) before your paper can be published. This form can be downloaded as a PDF. If you are unable to download the form, please contact the Production Editor at the address below and they will be able to email or FAX a form to you.
Once completed, please return the form to the Production Editor at the address below:
Chemical Biology & Drug Design
Blackwell Publishing Ltd
101 George Street
Edinburgh
Scotland
EH2 3ES
Fax:+44 (0) 131 226 3803
Email:cbdd@oxon.blackwellpublishing.com
Any article received by Blackwell Publishing with colour work will not be published until the form has been returned.
Proofs - should be returned with the least possible delay and with only essential corrections. Authors will be required to pay for any major alterations from their original manuscripts, and it may sometimes be necessary to disallow excessive changes.
The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site:
http://www.adobe.com/products/acrobat/readstep2.html
This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof.
Offprints
A PDF offprint of the online published article will be provided free of charge to the corresponding author, and may be distributed subject to the Publisher's terms and conditions. Paper offprints of the printed published article may be purchased if ordered via the method stipulated on the instructions that will accompany the proofs. Printed offprints are posted to the correspondence address given for the paper unless a different address is specified when ordered. Note that it is not uncommon for printed offprints to take up to eight weeks to arrive after publication of the journal. For order enquiries please email: offprint@cosprinters.com
OnlineEarly
Chemical Biology & Drug Design is covered by Blackwell Publishing's OnlineEarly service.
OnlineEarly articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. OnlineEarly articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated.
Because they are in final form, no changes can be made after online publication. The nature of OnlineEarly articles means that they do not yet have volume, issue or page numbers, so OnlineEarly articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found on the Web: http://www.doi.org/faq.html
Author material archive policy
Please note that unless specifically requested, Blackwell Publishing will dispose of all hardcopy or electronic material submitted two months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible if you have not yet done so.
OnlineOpen
OnlineOpen is a pay-to-publish service from Blackwell that offers authors whose papers are accepted for publication the opportunity to pay up-front for their manuscript to become open access (i.e. free for all to view and download) via the Blackwell Synergy website. Each OnlineOpen article will be subject to a one-off fee of ?300 (equivalent to $2600) to be met by or on behalf of the Author in advance of publication. Upon online publication, the article (both full-text and PDF versions) will be available to all for viewing and download free of charge. The print version of the article will also be branded as OnlineOpen and will draw attention to the fact that the paper can be downloaded for free via the Blackwell Synergy service.
Any authors wishing to send their paper OnlineOpen will be required to complete the combined payment and copyright licence form available from our website at: http://www.blackwellpublishing.com/pdf/cbdd_OOF.pdf (Please note this form is for use with OnlineOpen material ONLY.)
Once complete this form should be sent to the Production Editor along with the rest of the manuscript materials at the time of acceptance or as soon as possible after that (preferably within 24 hours to avoid any delays in processing). Do not inform the Editorial Office that you intend to publish your paper OnlineOpen before acceptance.
The copyright statement for OnlineOpen authors will read:
?[date] The Author(s)
Journal compilation ?[date] Blackwell Munksgaard
Online production tracking is now available for your article through Blackwell's Author Services.
Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit www.blackwellpublishing.com/bauthor for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
Cover Submissions
Authors are encouraged to submit original micrographs, molecular structures or graphic art for consideration as cover art. Submission of cover art is not limited to authors. Black and white or color images can be submitted, should be trimmed to fit into the photograph area of the cover (20.2-cm wide, 16-cm high), supplied at full size and accompanied by a cover legend.
Editorial Board
Editorial Information
Editor-in-Chief
Tomi K. Sawyer, Pfizer Research Technology Center, USA
Tel: +1 617 551 3307
E-mail: editor@cbdd.org
CB&DD Editorial Office
Christine Molle - Editorial Assistant
christine.molle@cbdd.org
Telephone Number: +1 781-279-3784
Fax Number: +1 781-279-3785
Senior Editors
Fahad Al-Obeidi, Sanofi-Aventis, USA
Hagan Bayley, Oxford University, UK
Stephen Fesik, Abbott, USA
Richard Friesner, Columbia University, USA
Carlos Garcia-Echeverria, Novartis, Switzerland
Victor Hruby, University of Arizona, USA
Henry Mosberg, University of Michigan, USA
Mark Murcko, Vertex, USA
Juswinder Singh, Conxcys, USA
Joseph Vacca, Merck, USA
Gabriel Waksman, University College London/Birbeck College, UK
Zhong-Yin Zhang , Indiana University School of Medicine, USA
Editorial Internship Team
Justin Noehre, Suffolk University
Thomas Sawyer, Saint Michael's College
Editorial Board
Dimitris Agrafiotis, Johnson & Johnson
Fernando Albericio, University of Barcelona
Karl-Heinz Altmann, ETH (Swiss Federal Institute of Technology)
Dario Altieri, University of Massachusetts Medical School
Paul Aristoff, Pfizer
Peter Atadja, Novartis Institutes for Biomedical Research
Jeffrey Aube, University of Kansas
V.N. Balaji, Jubilant Biosys
Tadhg Begley, Cornell University
Padmanabhan Balaram, Indian Institute of Science
George Barany, University of Minnesota
Annette Beck-Sickinger, University of Liepzig
Ettore Benedetti, University of Naples
Tom Blundell, University of Cambridge
Regine Bohacek, Boston De Novo
Robert Bonomo, Case Western Reserve University
Diane Boschelli, Wyeth
Philip Burton, ADMETRx
Stephen Caddick, University College London
Heather Carlson, University of Michigan
Jean Chmielewski, Purdue University
Michael Chorev, Harvard Medical School
Tim Clackson, ARIAD Pharmaceuticals
Claude Cohen, Synergix
Peter Connolly, Johnson & Johnson
Wayne Cody, MI Chemistry Consultants
Eugene Cordes, Vitae Pharmaceuticals
David Corey, Southwestern Medical Center
Wendy Cornell, Merck Research Laboratories
David Dalgarno, ARIAD Pharmaceuticals
Ben Davis, University of Oxford
Charles Deber, University of Toronto
William DeGrado, University of Pennsylvania
Benoit DePrez, Institut Pasteur de Lille
Renee DesJarlais, Johnson & Johnson
Yuan-Hua Ding, Pfizer
Jonathan Ellman, University of California-Berkeley
Michael Eck, Harvard Medical School
Joseph Eyermann, Astra-Zeneca
David Fairlie, University of Queensland
Gregg Fields, Florida Atlantic University
Carol Fierke, University of Michigan
David Floyd, Pharmacopeia
Michael Foley, Infinity Pharmaceuticals
James Foster, University of North Dakota
Roger Freidinger, Merck Research Laboratories
Ernesto Freire, John Hopkins University
Bruce Ganem, Cornell University
Thomas Gardella, Massachusetts General Hospital
Jason Gestwicki, University of Michigan
Lila Gierasch, University of Massachusetts-Amherst
Brendan Gilmore, Queen's University
Michael Gilson, University of Maryland
Gary Glick, University of Michigan
Nathalie Goudreau, Boehringer-Ingelheim
Indraneel Ghosh, University of Arizona
Nathanael Gray, Dana Farber Cancer Institute
Paolo Grieco, University of Naples
Stephen Haggarty, Broad Institute, MIT
Philip Hajduk, Abbott Laboratories
Andrew Hamilton, Yale University
Heidi Hamm, Vanderbilt University
Robert Hammer, Louisiana State University
Patrick Harran, Southwestern Medical Center
Carrie Haskell-Luevano, University of Florida-Gainesville
Robert Heinrikson, Proteos
Paul Hergenrother, University of Illinois
Ralph Hirschmann, University of Pennsylvania
Robert Hodges, University of Colorado
Wim Hol, University of Washington
Barry Honig, Columbia University
Andrew Hopkins, Pfizer
Richard Houghten, Torrey Pines Institute for Molecular Studies
Enoch Huang, Pfizer
Matt Jacobsen, University of California-San Francisco
Harren Jhoti, Astex Technology
David Jones, University College London
Natasha Kablaoui, Pfizer
Wieslaw Kazmierski, GlaxoSmithKline
Horst Kessler, Technical University-Munich
Alex Kiselyov, ChemDiv
Yoshiaki Kiso, Kyoto Pharmaceutical University
Gerhard Klebe, Philipps University
Ken Korzekwa, Merck Research Laboratories
Guido Kroemer, Institut Gustave-Roussy
Hugo Kubinyi, BASF
Cyrille Kuhn, Pfizer
Michael Lajiness, Eli Lilly & Company
Kit Lam, University of California-Davis
Joshua LeBaer, Harvard Medical School
Dominique Lessuise, Sanofi-Aventis
Guigen Li, Texas Tech University
Mark Lipton, Purdue University
Yan Luo, Abbott Laboratories
William Lubell, University of Montreal
Beth Lunney, Pfizer
Gerald Maggiora, University of Arizona
Bruce Maryanoff, Johnson & Johnson
Frank Mari, Florida Atlantic University
Garland Marshall, Washington University
Jean Martinez, Universit?Montpellier
Hans Matter, Sanofi-Aventis
Andy McCammon, University of California-San Diego
James McCarthy, Eli Lilly & Company
James McKerrow, University of California-San Francisco
Chester Metcalf III, Cubist Pharmaceuticals
Michael Michaelides, Abbott Laboratories
Dale Mierke, Brown University
Shahriar Mobashery, University of Notre Dame
Bradley Moore, University of Arizona
Andrew Mortlock, Astra-Zeneca
Steve Muchmore, Abbott Laboratories
Anil Nair, Sanofi-Aventis
Rick Neubig, University of Michigan
Gregory Nikiforoovich, Washington University
Richard Nugent, Pfizer
Robin Offord, University of Geneva
Michael Overduin, University of Birmingham
Robert Pearlstein, Novartis Institutes for Biomedical Research
Michael Pollastri, Pfizer
Joseph Provost, Minnesota State University-Moorhead
Tariq Rana, University of Massachusetts Medical School
Todd Rockway, Abbott Laboratories
Bernard Roques, Universit?Ren?Descartes
Vince Rotello, University of Massachusetts-Amherst
William Roush, Scripps-Florida
Leonard Rozamus, ARIAD Pharmaceuticals
Celia Schiffer, University of Massachusetts Medical School
Peter Schiller, University of Montreal
William Shakespeare, ARIAD Pharmaceuticals
Woody Sherman, Schrodinger
Yigong Shi, Princeton University
Sachdev Sidhu, Genentech
Adam Smith, Nobel Foundation
David Smith, Creighton University
Rob Stanton, Pfizer
Brian Stockman, Pfizer
Raji Sundaramoorthi, Chemistry Consultant
James Tam, Scripps University-Florida
Haile Techle, Pfizer
Suvit Thaisrivongs, Pfizer
Lynmarie Thompson, University of Massachusetts-Amherst
Claudio Toniolo, University of Padoa
Nicholas Turner, Manchester Interdisciplinary Biocenter
Greg Verdine, Harvard University
Michal Vieth, Eli Lilly & Company
Herbert Waldmann, Max Plank Institute
Dirk Tourwe, Vrije Universiteit Brussels
John Wade, University of Melbourne
Gerhard Wagner, Harvard University
Binghe Wang, Georgia State University
Yihan Wang, ARIAD Pharmaceuticals
James Wells, Sunesis & Univ California-San Franciscso
Manfred Weigele, Chemistry Advisor
Peter Wipf, University of Pittsburgh
Ronald Woodard, University of Michigan
Zhu-Jun Yao, Shanghai Institute of Organic Chemistry
Dennis Yamashita, GlaxoSmithKline
Xiaotian Zhu, ARIAD Pharmaceuticals
|
